Infectious Disease

HCV requires little or no monitoring to be handled successfully

December 06, 2020

1 min o’clock

Source / information

Source:

Solomon S. Late Breaking Oral Session 2. Presented at: The Liver Meeting Digital Experience; 13-16 November 2020.

Disclosure:
Naggie reports that he serves on an advisory committee or review panel for PRA / Bristol-Myers Squibb and FHI360; Member of the board of directors at HaborPath; Advice for BioMarin; Grant or research support from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Tacere; and as a shareholder for Vir.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Patients who received all medication upfront and were monitored via just two phone calls over 12 weeks achieved a sustained 95% virologic response, according to a presentation at the Digital Liver Meeting Experience.

“In terms of the barriers to caring for and treating people, especially in low-resource areas and low-to-middle-income countries, this is a big deal,” said Dr. Susanna Naggie from Duke University in an interview with Healio.

In this global study, the researchers showed that 95% of participants achieved a sustained virologic response with only two points of contact over the course of 12 weeks of treatment.

“Overall, the minimal surveillance approach really helps us understand how to do this safely,” said Naggie.

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Take homes in HCV

Related Articles